Anlotinib Clinical Trials
21 recruitingDrug
Phase 216Phase 33Phase 12Not Applicable2Phase 41
Showing 1–20 of 21 trials
Recruiting
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Breast CancerBreast NeoplasmHER2-negative Breast Cancer+7 more
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 2
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
Solid TumorsAdolescentsChildren
Cancer Institute and Hospital, Chinese Academy of Medical Sciences49 enrolled1 locationNCT06761417
Recruiting
Phase 3
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
Whole-Brain Radiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences134 enrolled1 locationNCT07443397
Recruiting
Phase 2Phase 3
Anlotinib Capsules in the Treatment for IPF/PF-ILDs
Interstitial Lung Diseases
First Affiliated Hospital of Wenzhou Medical University30 enrolled1 locationNCT05828953
Recruiting
Phase 2
A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
Breast Cancer
Zhejiang Cancer Hospital118 enrolled1 locationNCT07330544
Recruiting
Phase 2
To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital64 enrolled1 locationNCT06352008
Recruiting
Phase 1Phase 2
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
Craniopharyngiomas
Nanfang Hospital, Southern Medical University57 enrolled1 locationNCT06970145
Recruiting
Not Applicable
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
Small Cell Lung Cancer Recurrent
Fudan University39 enrolled1 locationNCT06258642
Recruiting
Phase 2
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
NSCLC Stage IV
Fudan University105 enrolled1 locationNCT04136535
Recruiting
Phase 2
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
SafetyLocally Advanced Non-Small Cell Lung CancerThoracic Radiotherapy
JIANYANG WANG44 enrolled1 locationNCT07037680
Recruiting
Phase 2
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Biliary Tract CancerCholangiocarcinomaGall Bladder Cancer+1 more
First Affiliated Hospital of Zhejiang University60 enrolled1 locationNCT07025174
Recruiting
Phase 2
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Nasopharyngeal Carcinoma
Sun Yat-sen University47 enrolled1 locationNCT06851247
Recruiting
Phase 2
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Solid TumorPrecision Medicine
Tianjin Medical University Second Hospital300 enrolled1 locationNCT06739395
Recruiting
Phase 2
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
Locally Advanced Thyroid Gland Carcinoma
West China Hospital75 enrolled1 locationNCT06482086
Recruiting
Phase 1
Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
Breast Cancer
Fudan University42 enrolled1 locationNCT06331169
Recruiting
Phase 4
Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
Soft Tissue SarcomaRadiotherapyDoxorubicin
Guangdong Provincial People's Hospital39 enrolled2 locationsNCT06506838
Recruiting
Phase 2
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Metastatic Colorectal Cancer
Fudan University44 enrolled1 locationNCT05229003
Recruiting
Phase 2Phase 3
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital1,200 enrolled1 locationNCT04322617
Recruiting
Phase 2
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
Cervical Cancer
Zhongnan Hospital35 enrolled1 locationNCT05817214
Recruiting
Not Applicable
The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study
Non-small Cell Lung Cancer
Ningbo Medical Center Lihuili Hospital30 enrolled1 locationNCT06188650